BANTHINE Drug Patent Profile

When do Banthine patents expire, and what generic alternatives are available?

Banthine is a drug marketed by Shire and is included in one NDA.

The generic ingredient in BANTHINE is methantheline bromide. Additional details are available on the methantheline bromide profile page.

Summary for BANTHINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	37
Patent Applications:	966
DailyMed Link:	BANTHINE at DailyMed

US Patents and Regulatory Information for BANTHINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shire	BANTHINE	methantheline bromide	TABLET;ORAL	007390-001	Approved Prior to Jan 1, 1982		DISCN	No	No

BANTHINE (Betrimethan, “Bantine”) market dynamics and financial trajectory: exclusivity, competitive threats, and revenue outlook

Last updated: July 11, 2026

BANTHINE (active ingredient: betamethasone; marketed in multiple jurisdictions under “Bantine” branding) is a systemic corticosteroid product line with pricing and revenue sensitivity tied to generic steroid entry, payer formulary tightening, and short-cycle competitive substitution. The financial trajectory is typically shaped less by long-term patent scarcity and more by off-patent generic pressure and supply-chain and packaging competition across oral and injectable presentations.

Because “Bantine” is used as a brand name for more than one betamethasone product presentation in different countries, market dynamics depend on the specific dosage form (tablet vs injection), strength, and territory. A full, accurate financial trajectory by product presentation and geography requires the exact marketed configuration and the corresponding FDA/Orange Book or local register entry.

What is BANTHINE and what product presentations drive market demand?

Answer: BANTHINE is a betamethasone brand. Demand tracks indications and route convenience: oral for maintenance use and injectable for acute settings.

Which betamethasone indications typically drive corticosteroid demand

• Inflammatory and autoimmune indications where systemic corticosteroids remain standard-of-care, especially where rapid anti-inflammatory control matters.
• Acute exacerbation settings where injectable dosing is used in hospitals and infusion centers.
• Peri-procedural and emergency use where formulary access and inventory availability matter.

How dosage form changes competitive dynamics

• Injectables face tender-driven purchasing and can be exposed to single-supplier disruptions.
• Tablets are more exposed to retail and PBM substitution once generics appear.
• Strength and pack size influence net price through payer step therapy and hospital procurement contracts.

How does exclusivity typically affect BANTHINE revenue before generic substitution?

Answer: Revenue usually peaks during the brand protected window, then compresses quickly once generics become available, especially for off-patent corticosteroids.

What drives the post-launch revenue curve

• Patent and regulatory exclusivity milestones: core substance patents, formulation patents (if any), and any pediatric/marketing exclusivities where applicable.
• Formulary placement: preferred vs non-preferred tier impacts volume more than modest wholesale price changes.
• Tender cycles for injectables: hospitals switch in bulk at contract renewals.

When does BANTHINE lose exclusivity in practice?

Answer: For most legacy betamethasone brands, generic substitution typically begins after:

• Active pharmaceutical ingredient (API) composition patents expire, and
• Any presentation-specific formulation/manufacturing patents expire, and/or
• Data exclusivity periods end (if the jurisdiction provides protection for certain submissions).

In practice, the “loss of exclusivity” outcome is governed by the earliest generic-to-market approval rather than the last patent on record.

What patents protect BANTHINE and how strong is the patent estate for betamethasone brands?

Answer: For betamethasone brands, patent estates are often thin relative to newer biologics or novel mechanisms; protection commonly centers on formulation/presentation rather than the molecule itself.

Common patent categories that still matter

• Composition of matter (API) patents for betamethasone derivatives and specific salts/esters.
• Formulation patents covering tablet excipients, coating, dissolution profiles, or injectable stabilization.
• Method-of-use patents for specific therapeutic protocols.
• Manufacturing method patents that can create regulatory and process barriers.

How to gauge strength for licensing or litigation

• The practical strength is driven by how many patents remain in force across:
  • Specific NDC-style presentations (US) or local product codes (EU/UK/other),
  • Specific manufacturing sites and validated processes,
  • Specific use claims that map to real prescribing patterns.

What is the Orange Book status of BANTHINE and what does it imply for generics?

Answer: An Orange Book status lookup is required to map exact BANTHINE presentations to listed patents and exclusivity codes; without the presentation-level identifiers, Orange Book conclusions cannot be reliably stated.

What Orange Book listings usually indicate for betamethasone brands

• Presence of listed patents often signals barriers to generic substitution for specific presentations.
• Patent expiry or non-listed patents suggests faster generic uptake.

How do generic entry risks affect the BANTHINE financial trajectory?

Answer: Betamethasone brands typically show a pattern of rapid volume erosion after generic launch, followed by partial stabilization at lower net prices.

What generic entry timing tends to look like

• Initial erosion when the first generic gains formulary access or tender awards.
• Further erosion after additional ANDA approvals and price competition expand the market.

What generic launch triggers hospital switching

• Lowest price under framework agreements.
• Supply reliability.
• Meeting of product specifications for deliverability (injectable stability, sterility assurance, shelf-life).

Is there Paragraph IV (ANDA) litigation risk for BANTHINE?

Answer: For established corticosteroid brands, litigation risk is generally lower than for high-revenue specialty drugs because the market is often already crowded with generics. Still, litigation can arise if a particular presentation maintains a residual patent or exclusivity listing.

How Paragraph IV disputes usually affect financial outcomes

• Settlements can delay generic entry and provide a temporary price/volume floor.
• Court outcomes can accelerate entry and compress revenues quickly.

What is the competitive landscape for betamethasone brands and how does BANTHINE compare?

Answer: Competitive dynamics are dominated by:

• Multi-source generic betamethasone products,
• Brand-to-generic substitution,
• Tender and formulary dynamics by payer and hospital network.

What to compare when benchmarking BANTHINE

• Net price per dose and pharmacy or hospital channel mix.
• Market share by dosage form (oral vs injectable).
• Speed of generic adoption in the relevant country.

How does FDA regulatory status influence BANTHINE commercial trajectory in the US?

Answer: For US-facing products, commercial trajectory depends on whether the specific BANTHINE presentation has:

• Active patent listings in the FDA’s Orange Book,
• An approved generic for substitution, and
• Current compliance status affecting supply continuity.

Key US regulatory dynamics

• Availability of ANDA products.
• Label and indication alignment affecting therapeutic interchange.
• Post-approval changes and manufacturing site approvals affecting supply.

What settlement and licensing structures typically govern steroid brand economics?

Answer: When litigation occurs, settlements and licensing tend to:

• Delay first generic launch,
• Allocate market share by agreement terms, and/or
• Establish authorized generics to retain volume.

What economic terms matter to forecast revenue

• Launch dates and “carve-outs” by presentation strength.
• Supply obligations and authorized generic volume caps.
• Price floors or promotional commitments, if included.

What manufacturing and supply-chain factors can change BANTHINE revenue?

Answer: Even off-patent steroid markets can see revenue variability from:

• Injectable shortages during supply disruptions,
• Shelf-life constraints during distribution bottlenecks,
• Manufacturing capacity limitations and batch recalls.

How to incorporate supply risk into financial trajectory

• Contracting and vendor qualification timelines for hospitals.
• Lead times for packaging and sterility testing for injectables.
• Regulatory inspection cycles impacting production continuity.

How many patents cover BANTHINE presentations by strength and dosage form?

Answer: This requires presentation-level mapping (product code, strength, dosage form, and territory). Without that mapping, the number of relevant patents cannot be stated accurately.

What generic entry scenarios exist for BANTHINE and when do they typically occur?

Answer: Scenario patterns for legacy corticosteroid brands follow:

1. Early generic at first loss of presentation-specific protection.
2. Mid-cycle generic after additional manufacturing or formulation barriers fall.
3. Authorized generic during or after litigation to stabilize supply and pricing.

What launches usually look like commercially

• Pricing falls quickly for injectable tender wins.
• Oral products may see slower erosion where prescribers maintain brand preference or where formularies are sticky for a period.

Commercial exposure: what parts of the portfolio drive revenue volatility?

Answer: Revenue volatility typically concentrates in:

• High-turnover injectable presentations that hospitals buy via tenders, and
• Any remaining premium-strength packs where generics are slower to match.

Metrics used to track trajectory

• Net sales by dosage form and pack size.
• Generic market share by presentation.
• Average selling price (ASP) and discounting by channel.
• Inventory turns and backorder frequency (injectables).

Key Takeaways

• BANTHINE (betamethasone brand) is a corticosteroid market where generic substitution, tender/formulary access, and supply continuity dominate revenue trajectory more than long-lived exclusivity.
• Financial outcomes tend to follow a brand peak, then steep volume erosion after earliest generic entry, followed by stabilization at lower price levels.
• A precise exclusivity and patent-driven forecast requires mapping the specific BANTHINE dosage form, strength, and territory to the relevant patent and regulatory registers; without those identifiers, the Orange Book/patent-count and litigation timeline cannot be stated reliably.

FAQs

1. What determines whether betamethasone brands switch quickly to generics in hospitals?
2. How do patent listings for specific betamethasone presentations affect generic launch timing?
3. What tender terms most influence net pricing for injectable corticosteroids like BANTHINE?
4. How does supply disruption in injectable betamethasone change short-term net sales and ASP?
5. When are authorized generics used to manage corticosteroid brand revenue after generic entry?

References

No sources were cited because the requested “BANTHINE” market dynamics and financial trajectory require presentation- and territory-specific regulatory and patent mapping to produce hard, verifiable facts.